Medicines losing patent protection

MonthYear

June 2026

6 medicines lost their last listed patent or exclusivity in June 2026.

Jun 7Emflaza · Tablet (oral)deflazacort · Ptc Therapeutics Inc
Jun 7Emflaza · Suspension (oral)deflazacort · Ptc Therapeutics Inc
Jun 16Cambiadiclofenac potassium · Cosette Pharmaceuticals Inc
Jun 16Supprelin LAhistrelin acetate · Endo Operations Ltd
Jun 27Aplenzinbupropion hydrobromide · Bausch Health US LLC
Jun 28Thiolatiopronin · Mission Pharmacal Co

Dates are the patent and exclusivity end dates listed in the FDA's Orange Book, in its data up to October 9, 2026. Patents can be extended, challenged in court or settled, so a generic may come earlier, later or not at all. This is not legal or medical advice.

About the data·Privacy·Credits